A tiger behind many doors: multiple genetic pathways to malignant glioma

doi:10.1016/S0168-9525(00)89125-8

Trends in Genetics

Volume 11, Issue 10, October 1995, Pages 412-415

https://doi.org/10.1016/S0168-9525(00)89125-8 Get rights and content

Abstract

Malignant gliomas are the most common primary human brain tumours, but their classification remains controversial and effective therapies remain elusive. As a result, malignant gliomas have come under intense scientific scrutiny, in the hope of elucidating the molecular basis of glial tumourigenesis. These studies have yielded insights into the genetic events that underlie glioma formation and progression, and have shown multiple distinct genetic pathways that lead to the common malignant endpoint of glioblastoma multiforme. Such genetic pathways mirror clinicopathological avenues of glioma progression and suggest that molecular genetic approaches might have clinical utility in the coming years.

References (38)

B. Vogelstein et al.
Trends Genet.
(1993)
G.N. Fuller et al.
Mutat. Res.
(1992)
F.R. Stockton
The Lady or the Tiger?, and other stories
(1884)
D.P. Lane
Nature
(1992)
D.N. Louis
J. Neuropathol. Exp. Neurol.
(1994)
Y. Cho et al.
Science
(1994)
G. Reifenberger
Cancer Res.
(1993)
M.-P. Rubio
Cancer Res.
(1993)
L.M. Alderson
Cancer Res.
(1995)
M. Hermanson
Cancer Res.
(1992)

M. Debbas et al.

Genes Dev.

(1993)

C.D. James

Cancer Res.

(1988)

D. Fults et al.

Cancer Res.

(1990)

M.-P. Rubio

Cancer Res.

(1994)

J.A. Rey

Int. J. Cancer

(1992)

J.W. Henson

Ann. Neurol.

(1994)

A. Kamb

Science

(1994)

J. Jen

Cancer Res.

(1994)

W. Arap

Cancer Res.

(1995)

Cited by (193)

Immunotoxin Therapy for Brain Tumors
2017, Translational Immunotherapy of Brain Tumors
Despite a multimodal approach involving surgery, radiotherapy, and chemotherapy, the median survival for malignant brain tumor patients is limited to 15–19 months. To improve glioblastoma patient survival, novel therapies targeting the heterogeneous tumor cell population are needed. Advances in understanding the molecular features of patients' tumors have led to the development of personalized tumor-targeted therapies that are more effective and less toxic. Immunotoxins, a novel class of antibody/ligand-toxin conjugates, have been developed during the last two decades for the treatment of brain tumors. The antibody/ligand domain of the immunotoxin binds to the target antigen on the tumor cell surface, whereas the toxin payload kills the tumor cells by inhibiting protein synthesis. Advances in immunotoxin delivery and monitoring of immunotoxin distribution in tumors are overcoming the challenges in the brain tumor therapy field. Herein, we summarize the different antiglioma immunotoxins that are at the preclinical and clinical stages of development.
Tumor progression: Chance and necessity in Darwinian and Lamarckian somatic (mutationless) evolution
2012, Progress in Biophysics and Molecular Biology
Current investigation of cancer progression towards increasing malignancy focuses on the molecular pathways that produce the various cancerous traits of cells. Their acquisition is explained by the somatic mutation theory: tumor progression is the result of a neo-Darwinian evolution in the tissue. Herein cells are the units of selection. Random genetic mutations permanently affecting these pathways create malignant cell phenotypes that are selected for in the disturbed tissue. However, could it be that the capacity of the genome and its gene regulatory network to generate the vast diversity of cell types during development, i.e., to produce inheritable phenotypic changes without mutations, is harnessed by tumorigenesis to propel a directional change towards malignancy? Here we take an encompassing perspective, transcending the orthodoxy of molecular carcinogenesis and review mechanisms of somatic evolution beyond the Neo-Darwinian scheme. We discuss the central concept of “cancer attractors” – the hidden stable states of gene regulatory networks normally not occupied by cells. Noise-induced transitions into such attractors provide a source for randomness (chance) and regulatory constraints (necessity) in the acquisition of novel expression profiles that can be inherited across cell divisions, and hence, can be selected for. But attractors can also be reached in response to environmental signals – thus offering the possibility for inheriting acquired traits that can also be selected for. Therefore, we face the possibility of non-genetic (mutation-independent) equivalents to both Darwinian and Lamarckian evolution which may jointly explain the arrow of change pointing toward increasing malignancy.
WHO grade-specific comparative genomic hybridization pattern of astrocytoma - A meta-analysis
2010, Pathology Research and Practice
To detect novel genetic alterations, many astrocytomas have been investigated by comparative genomic hybridization (CGH). To identify aberration profiles characteristic of World Health Organization (WHO) grade I, II, III, and IV astrocytoma, we performed a meta-analysis of detailed genome wide CGH data of all 467 cases published so far. After expansion of all given aberrations to the maximum of 850 GTG-band resolution, the frequencies of genetic imbalances were calculated for each chromosomal band, separately for all four WHO grades.
Low-grade astrocytoma has already demonstrated one characteristic of glioblastoma multiforme, gain of chromosome 7 with a hot spot at 7q32, but without loss of chromosome 10. In anaplastic astrocytoma, a more complex aberration pattern emerges from diffuse genetic imbalances. Gains of 7q32–q36 and 7p12 become the most frequent aberrations at chromosome 7. In glioblastoma multiforme, coarse aberrations like +7, −9p, −10, and −13 represent the most frequent aberrations as a characteristic pattern. In contrast to lower tumor grades, glioblastoma multiforme demonstrates +7p12 as the most frequently affected band on chromosome 7.
To quantify the gradual transition from WHO grade II–IV astrocytoma, we calculated the relative increase and decrease in frequency for each detected aberration of the tumor genome. The most pronounced and diverse changes of genetic material occur at the virtual transition from low-grade to anaplastic astrocytoma. Further transition to glioblastoma multiforme is characterized by gain of 1p, chromosome 7, and loss of chromosome 10.
Summing up, the expansion of the CGH results to the 850 GTG-band resolution enabled a meta-analysis to visualize WHO grade-specific aberration profiles in astrocytoma.
Astrocytic neoplasms of the central nervous system and orbit: A morphologic perspective
2010, Seminars in Diagnostic Pathology
Citation Excerpt :
The molecular pathology of GBM is complex. Earlier studies defined the “primary” and “secondary” variants.48 The most common molecular subtype is the primary GBM with EGFR amplification, PTEN mutation, and CDKN2A deletion (p16).
Astrocytic neoplasms constitute a highly diverse category of neoplasms in the central nervous system and the orbit that span from almost benign to highly malignant neoplasms. Most tumors in the former category are potentially cured by surgery alone, while the latter group of tumors do not respond to any form of current treatment. The most critical advance in our understanding of the pathology of these tumors has divided this group into circumscribed (or solid) and infiltrating (or diffuse) categories. These two categories differ from one another in virtually every aspect and their distinction has become the principle role of the pathologist in guiding appropriate management. There is increasing insight into the biology of these neoplasms but the fundamental role of the pathologist still remains the correct morphological recognition. This short review highlights the most pertinent features of neoplasms considered within this diverse family.
Mechanisms of Local Immunoresistance in Glioma
2010, Neurosurgery Clinics of North America
Overexpression of Nrp/b (nuclear restrict protein in brain) suppresses the malignant phenotype in the C6/ST1 glioma cell line
2009, Journal of Steroid Biochemistry and Molecular Biology
Upon searching for glucocorticoid-regulated cDNA sequences associated with the transformed to normal phenotypic reversion of C6/ST1 rat glioma cells, we identified Nrp/b (nuclear restrict protein in brain) as a novel rat gene. Here we report on the identification and functional characterization of the complete sequence encoding the rat NRP/B protein. The cloned cDNA presented a 1767 nucleotides open-reading frame encoding a 589 aminoacids residues sequence containing a BTB/POZ (broad complex Tramtrack bric-a-brac/Pox virus and zinc finger) domain in its N-terminal region and kelch motifs in its C-terminal region. Sequence analysis indicates that the rat Nrp/b displays a high level of identity with the equivalent gene orthologs from other organisms. Among rat tissues, Nrp/b expression is more pronounced in brain tissue. We show that overexpression of the Nrp/b cDNA in C6/ST1 cells suppresses anchorage independence in vitro and tumorigenicity in vivo, altering their malignant nature towards a more benign phenotype. Therefore, Nrp/b may be postulated as a novel tumor suppressor gene, with possible relevance for glioblastoma therapy.

View all citing articles on Scopus

View full text

Trends in Genetics

ReviewA tiger behind many doors: multiple genetic pathways to malignant glioma

Abstract

Trends Genet.

Mutat. Res.

The Lady or the Tiger?, and other stories

Nature

J. Neuropathol. Exp. Neurol.

Science

Cancer Res.

Cancer Res.

Cancer Res.

Cancer Res.

Genes Dev.

Cancer Res.

Cancer Res.

Cancer Res.

Int. J. Cancer

Ann. Neurol.

Science

Cancer Res.

Cancer Res.

Review
A tiger behind many doors: multiple genetic pathways to malignant glioma